Affiliation:
1. Department of Pharmacy/Research Ward, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
Abstract
A novel, robust and sensitive HPLC-MS/MS method was firstly developed and fully validated for quantitating MRTX849 in plasma. This analytical method was successfully applied for a pharmacokinetic study of MRTX849 at a dose of 15 mg kg−1 in rats.
Funder
National Natural Science Foundation of China
Natural Science Foundation of Beijing Municipality
Beijing Municipal Administration of Hospitals
Publisher
Royal Society of Chemistry (RSC)
Subject
Electrochemistry,Spectroscopy,Environmental Chemistry,Biochemistry,Analytical Chemistry
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Development and validation of an ultra‐performance liquid chromatography–tandem mass spectrometry method to quantify the small molecule inhibitors adagrasib, alectinib, brigatinib, capmatinib, crizotinib, lorlatinib, selpercatinib, and sotorasib in human plasma;Biomedical Chromatography;2024-08-13
2. Application of newly developed and validated LC-MS/MS method for pharmacokinetic study of adagrasib and pembrolizumab simultaneously in rat plasma;Journal of Chromatography B;2024-07
3. Pharmacokinetics, Bioavailability, and Tissue Distribution of the Kirsten Rat Sarcoma Inhibitor Adagrasib in Rats Using UPLC-MS/MS;Drug Design, Development and Therapy;2024-01
4. Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs;Journal of Chromatography B;2023-12
5. Development and validation of an HPLC–MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue‐related matrices;Biomedical Chromatography;2023-08-19